Privatlivspræferencer
Inderes bruger cookies for at give en bedre brugeroplevelse og en personlig service. Ved at give samtykke til brugen af cookies kan vi udvikle en endnu bedre service og vil kunne levere indhold, der er interessant for dig.
  • Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Magle Chemoswed Holding Reports Financial Results For Second Quarter 2026

MAGLESelskabsmeddelelse12.08.2026, 18.15
Download udgivelse

Early signs of stabilisation in a year of transition

Q2 2026 KEY INDICATORS (Apr–Jun)

  • Total revenue amounted to 74.6 MSEK (55.2)
  • EBITDA equalled 1.5 MSEK (-20.6)
  • Operating profit (EBIT) was -13.1 MSEK (-29.0)
  • Profit after tax amounted to -17.0 MSEK (-27.8)

Jan–Jun 2026 KEY INDICATORS (H1)

  • Total revenue amounted to 146.3 MSEK (140.3)
  • EBITDA equalled -5.0 MSEK (-1.8)
  • Operating profit (EBIT) was -30.9 MSEK (-26.9)
  • Profit after tax amounted to -39.0 MSEK (-29.0)

Aaron Wong, Interim CEO of Magle Group, commented:

"The second quarter showed early signs of stabilisation. Revenue recovered against the second quarter last year, supported by improved production efficiences. EBITDA in the second quarter was positive, which was an improvement both on the same period last year and preceding quarter.

These are early indicators. The Group remains loss-making, the quarter still carried substantial non-recurring costs connected with the restructuring, and the reported figures should not be read as the run-rate of the business. In parallel, we have agreed with our principal bondholders the terms of a recapitalisation of the balance sheet, which is now being implemented and on which the Group's continued operation depends. There remains a great deal to do. As stated in the first quarter, the turnaround is expected to take twelve to eighteen months, and our progress is better judged over that period than on any single quarter."

Contacts


Aaron Wong, Interim CEO, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

About Us


The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. Today, the Group includes two operational areas. Magle Chemoswed – a contract manufacturing organization (CMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle Biopolymers A/S - a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglebiopolymers.com

Redeye Nordic Growth AB is the company's Certified Adviser.

This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-08-12 18:15 CEST.

Attachments


Q2 2026 Interim Report